An official website of the United States government
Home
Name
Palbociclib
Alternate Names
IBRANCE
PD 0332991
PD 332991
Abbreviations
None
Category
Chemotherapy
Subcategory
CDK Inhibitor
NSC Number
None
Primary Site
Breast
Histology
None
Remarks
The FDA has granted a breakthrough therapy designation to Palbociclib (PD 0332991). this drug has been approved for use in combination with letrozole for the treatment of postmenopausal women with ER+, HER2 negative locally advanced or metastatic breast cancer as an initial endocrine-based therapy.
February 19, 2016 FDA approved palbociclib (IBRANCE Capsules, Pfizer, Inc.) in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
February 19, 2016 FDA approved palbociclib (IBRANCE Capsules, Pfizer, Inc.) in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
Coding
This drug should be coded
